{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:28:17Z","timestamp":1765758497236,"version":"3.40.5"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,29]],"date-time":"2017-09-29T00:00:00Z","timestamp":1506643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.canep.2017.08.001","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T19:31:51Z","timestamp":1506627111000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Trends in prescribing systemic treatment and overall survival for non-small cell lung cancer stage IIIB\/IV in the Netherlands: 2008\u20132012"],"prefix":"10.1016","volume":"51","author":[{"given":"Bas J.M.","family":"Peters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9587-9318","authenticated-orcid":false,"given":"Christine M.","family":"Cramer-vd Welle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur A.J.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz M.N.H.","family":"Schramel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewoudt M.W.","family":"van de Garde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2017.08.001_bib0005","unstructured":"Nederlandse Kankerregistratie, Available at: http:\/\/www.cijfersoverkanker.nl\/home-27.html, Accessed 9\/25\/2014, (2014)."},{"key":"10.1016\/j.canep.2017.08.001_bib0010","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proc."},{"issue":"Suppl 3","key":"10.1016\/j.canep.2017.08.001_bib0015","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/annonc\/mdu199","article-title":"Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"25","author":"Reck","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canep.2017.08.001_bib0020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.lungcan.2016.04.007","article-title":"Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not","volume":"97","author":"Brule","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canep.2017.08.001_bib0025","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1002\/cncr.29386","article-title":"Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: are patients undertreated?","volume":"121","author":"Sacher","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2017.08.001_bib0030","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.lungcan.2012.04.019","article-title":"Survival among non-small cell lung cancer patients with poor performance status after first line chemotherapy","volume":"77","author":"Salloum","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.canep.2017.08.001_bib0035","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2017.08.001_bib0040","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2002.02.068","article-title":"Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer","volume":"20","author":"Scagliotti","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2017.08.001_bib0045","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/S1470-2045(15)70046-X","article-title":"Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study","volume":"16","author":"Paz-Ares","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canep.2017.08.001_bib0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006724","article-title":"A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer","volume":"5","author":"Groene","year":"2015","journal-title":"BMJ Open"},{"key":"10.1016\/j.canep.2017.08.001_bib0055","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1200\/JCO.2012.45.9792","article-title":"Comparative effectiveness research in oncology: an overview","volume":"30","author":"Lyman","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"January (3)","key":"10.1016\/j.canep.2017.08.001_bib0060","article-title":"Antineoplastic treatment of advanced-Stage non-Small-Cell lung cancer: treatment, survival, and spending (2000 to 2011)","author":"Bradley","year":"2017","journal-title":"J. Clin. Oncol."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782117301285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782117301285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T03:00:43Z","timestamp":1535338843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782117301285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":12,"alternative-id":["S1877782117301285"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2017.08.001","relation":{},"ISSN":["1877-7821"],"issn-type":[{"type":"print","value":"1877-7821"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in prescribing systemic treatment and overall survival for non-small cell lung cancer stage IIIB\/IV in the Netherlands: 2008\u20132012","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2017.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}